



Investment Summary

Location: Los Angeles, California
Industry: Healthcare Information Technology
Company: Medversant Technologies, LLC

Acquisition Date: April 2018
Facility Amount: \$1,000,000
Investment Term: 36 Months

Background:

Founded in 1999 and headquartered in Los Angeles, CA, Medversant Technology LLC (“Medversant” or the “Company”) is a healthcare information technology company that provides solutions for a critical component of healthcare administration – the management of healthcare provider information and medical credentialing within health plans, hospitals, government agencies, and other healthcare organizations. Medversant’s solutions cut costs and improve data quality while increasing provider collaboration, promoting decreased liability exposure and improving patient care. Customers include well-known companies such as Humana, Cigna, and Conduent, to name a few. Additional customers include healthcare plans, public sector plans (Medicaid), pharmacies and pharmacy benefits managers (PBMS) and providers (i.e. doctors). Medversant services are provided through a Web-based platform, which is shared with the customer. This creates greater transparency and seamless service delivery. Its data management platform is sold as One Source. From the process of data collection through the completion of the audit, there is no need to deal with multiple vendors.



Collateral:

Medversant will be utilizing proceeds from the SQN Asset Income Fund V, LP (“SQN Fund V”) facility to acquire new servers, switches, and support components. A server is a computer designed to process requests and deliver data to another computer over the internet or local networks. A switch serves as a controller to the network, enabling networked devices to talk to each other efficiently. The equipment is required to support Medversant’s strong growth as the servers are critical to the management of client’s documents and data. Due to the business essential nature of the equipment, SQN Fund V’s risk is mitigated in the event that the Company encounters cash flow problems as Medversant will have the incentive to pay SQN Fund V over non-core and/or non-revenue generating assets.

About the Sponsor:

Arboretum Investment Advisors, LLC (“Arboretum IA”) is an alternative asset manager dedicated to non-correlated investment strategies, built to diversify investor portfolios, thereby striving to create a better investor experience. Arboretum IA currently provides asset management and asset servicing to third party fund managers and works with a diverse array of clients including retail investors, private wealth managers and family offices. Arboretum IA is a Registered Investment Advisor and is charged with asset management and oversight of over \$225M as of December 31, 2018.

General Disclosures

This is neither an offer to sell nor a solicitation of an offer to buy the securities described herein. An offering is made only by the prospectus. This sales and advertising literature must be read in conjunction with the prospectus in order to understand fully all of the implications and risks of the offering of securities to which it relates. A copy of the prospectus must be made available to you in connection with this offering. You should purchase units only if you meet all of the investor suitability requirements and are prepared to hold your investment for the entire term.



*Securities offered through American Elm Distribution Partners, LLC, Member FINRA/SIPC
All entities are affiliated.*

Contact Us

American Elm Distribution Partners, LLC
100 Arboretum Drive, Suite 105
Portsmouth, NH 03801

Phone: 800-258-6610
www.thearboretumgroup.com

IMPORTANT RISK DISCLOSURES

An investment in SQN Asset Income Fund V, LP involves a high degree of risk and there can be no assurance that the investment objectives of this program will be attained. Some of the risks associated with this offering include the following: no prior operating history; “blind pool” offering; this is a “best efforts” offering and some or all of our shares may not be sold; our ability to diversify our portfolio will depend on our ability to raise funds in this offering; no public market currently exists for our shares; it may be difficult to sell your shares, and if you do, it will likely be at a substantial discount; fees to affiliates, illiquidity, leveraging, and performance may be affected by unanticipated declines in residual value or changes in the market; there are material federal income tax risks associated with the offering of the fund’s units; Investors will be required to bear the financial risks of this investment for an indefinite period of time. A substantial portion, and possibly all, of the cash distributions you receive from the

fund will be a return of capital and not a return on capital, and the amount and rate of cash distributions could vary and are not guaranteed; the amounts paid as cash distributions will reduce the amount of funds available for investment in equipment, as a result investors should not need to rely on the cash distributions as a regular source of cash.

Neither the Securities and Exchange Commission, nor any state securities regulator has approved or disapproved of these securities or determined if the prospectus is truthful or complete. The fund is not registered under the investment company act. Accordingly, the act’s provisions (which, among other matters, require investment companies to have a majority of disinterested directors) will not be applicable. Any representation to the contrary is a criminal offense. Images are for illustrative purposes only.